ImmuCell Statistics
Total Valuation
ImmuCell has a market cap or net worth of $29.37 million. The enterprise value is $39.92 million.
Important Dates
The last earnings date was Wednesday, November 13, 2024, after market close.
Earnings Date | Nov 13, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
ImmuCell has 7.83 million shares outstanding. The number of shares has increased by 1.57% in one year.
Current Share Class | 7.83M |
Shares Outstanding | 7.83M |
Shares Change (YoY) | +1.57% |
Shares Change (QoQ) | +4.54% |
Owned by Insiders (%) | 33.42% |
Owned by Institutions (%) | 14.75% |
Float | 4.71M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 1.19 |
Forward PS | n/a |
PB Ratio | 1.20 |
P/TBV Ratio | 1.07 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 1.67 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.11, with a Debt / Equity ratio of 0.59.
Current Ratio | 3.11 |
Quick Ratio | 1.37 |
Debt / Equity | 0.59 |
Debt / EBITDA | 21.73 |
Debt / FCF | n/a |
Interest Coverage | -17.96 |
Financial Efficiency
Return on equity (ROE) is -14.54% and return on invested capital (ROIC) is -4.04%.
Return on Equity (ROE) | -14.54% |
Return on Assets (ROA) | -3.85% |
Return on Capital (ROIC) | -4.04% |
Revenue Per Employee | $301,747 |
Profits Per Employee | -$48,241 |
Employee Count | 79 |
Asset Turnover | 0.54 |
Inventory Turnover | 2.28 |
Taxes
In the past 12 months, ImmuCell has paid $5,368 in taxes.
Income Tax | 5,368 |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -24.39% in the last 52 weeks. The beta is 0.57, so ImmuCell's price volatility has been lower than the market average.
Beta (5Y) | 0.57 |
52-Week Price Change | -24.39% |
50-Day Moving Average | 3.61 |
200-Day Moving Average | 4.36 |
Relative Strength Index (RSI) | 50.20 |
Average Volume (20 Days) | 14,495 |
Short Selling Information
The latest short interest is 4,009, so 0.05% of the outstanding shares have been sold short.
Short Interest | 4,009 |
Short Previous Month | 8,184 |
Short % of Shares Out | 0.05% |
Short % of Float | 0.09% |
Short Ratio (days to cover) | 0.23 |
Income Statement
In the last 12 months, ImmuCell had revenue of $23.84 million and -$3.81 million in losses. Loss per share was -$0.49.
Revenue | 23.84M |
Gross Profit | 6.89M |
Operating Income | -2.74M |
Pretax Income | -3.89M |
Net Income | -3.81M |
EBITDA | -49,834 |
EBIT | -2.74M |
Loss Per Share | -$0.49 |
Full Income Statement Balance Sheet
The company has $3.81 million in cash and $15.53 million in debt, giving a net cash position of -$11.72 million or -$1.50 per share.
Cash & Cash Equivalents | 3.81M |
Total Debt | 15.53M |
Net Cash | -11.72M |
Net Cash Per Share | -$1.50 |
Equity (Book Value) | 26.41M |
Book Value Per Share | 2.99 |
Working Capital | 9.42M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$362,117 and capital expenditures -$350,853, giving a free cash flow of -$712,970.
Operating Cash Flow | -362,117 |
Capital Expenditures | -350,853 |
Free Cash Flow | -712,970 |
FCF Per Share | -$0.09 |
Full Cash Flow Statement Margins
Gross margin is 28.92%, with operating and profit margins of -11.49% and -15.99%.
Gross Margin | 28.92% |
Operating Margin | -11.49% |
Pretax Margin | -15.96% |
Profit Margin | -15.99% |
EBITDA Margin | -0.21% |
EBIT Margin | -11.49% |
FCF Margin | -13.02% |